Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents

  title={Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents},
  author={Gabriel Eilon and J Gu and Lewis M. Slater and Kaoru Hara and John W. Jacobs},
  journal={Cancer Chemotherapy and Pharmacology},
  • G. Eilon, J. Gu, J. Jacobs
  • Published 2000
  • Biology, Chemistry, Medicine
  • Cancer Chemotherapy and Pharmacology
Purpose: The overall purpose of this study was to determine the potential efficacy of epoxide-containing piperazines as a new class of anti-cancer agents. Two representative compounds, specifically NCO-700, a 4-trimethoxyphenyl-substituted epoxide-piperazine, and TOP-008, a 4-phenylpropenyl-substituted epoxide-piperazine were tested in cytotoxic assays with human breast and prostate cancer cell lines. A second objective was to determine if these two compounds had anti-cancer activity in vivo… 

Novel piperazine induces apoptosis in U937 cells.

It is shown that BIPP induces dose-responsive apoptotic cell death in U937 cells by intrinsic mechanisms of apoptosis, and the data suggests that it may be a potential therapeutic agent for human myeloid leukemia.

Original Article Novel piperazine induces apoptosis in U937 cells

Novel evidence is provided that 1,4-bis-(4-(1H-benzo[d] imi-dazol-2-yl-phenyl)) piperazine (BIPP) induces apoptosis in leukemia cells without affecting normal monocytes and that BIPP utilizes intrinsic apoptotic sig-naling mechanisms to induce leukemia cell death.

Sildenafil (VIAGRATM): A Promising Anticancer Drug Against Certain Human Cancer Cell Lines

The study evaluated sildenafil cytototoxic activity in vitro against mammalian cell lines: MCF-7, HCT-116, HeLa cells and A-549 cells with their IC50 values and shed light on the antitumor activity of sildanafil and its possible impact on potentiating of cytokines, antitUMor and anti-inflammatory markers in tumour cells.

Cytotoxic Activity of Cyclamen Persicum Ethanolic Extract on MCF-7, PC-3 and LNCaP Cancer Cell Lines

Results displayed that C. persicum is a good source for natural products with antitumor compounds that can be further exploited for the development of a potential therapeutic anticancer agent.

Cancer Cell Cytotoxicities of 1-(4-Substitutedbenzoyl)-4-(4-chlorobenzhydryl)piperazine Derivatives

Time-dependent cytotoxicity analysis of compound 5a indicated the long-term in situ stability of this compound, and all compounds showed significant cell growth inhibitory activity on the selected cancer cell lines.

Apoptosis of breast cancer cells: modulation of genes for glycoconjugate biosynthesis and targeted drug delivery.

The induction of apoptosis in breast and other cancer cells by various new chemicals is discussed, and the biosynthesis and regulation of GSLs in nonapoptotic and apoptotic cancer cells are discussed.

ects and mechanisms of emodin on cell death in human lung squamous cell carcinoma

It is suggested that emodin induces CH27 cell death by Bax death pathway and Fas pathway and the activation of caspase-3, caspasing-9 and caspases-8 is an important determinant of apoptotic death induced by emodIn.

Synthesis and evaluation of 1-benzhydryl-sulfonyl-piperazine derivatives as inhibitors of MDA-MB-231 human breast cancer cell proliferation

A series of novel 1-benzhydryl-sulfonyl-piperazine derivatives 7(a-e) were designed by a nucleophilic substitution reaction of 1-benzhydryl-piperazine with various sulfonyl chlorides and

Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.

The data indicate that the combined treatment of Apo2L/TRAIL and CPT-11 achieves tumor control in prostate cancer tumors through regulation of Bcl-2 family proteins and potent activation of caspases and PARP cleavage.



Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells.

Green tea may protect against cancer by causing cell cycle arrest and inducing apoptosis, and needs to be evaluated in human trials.

Cancer metastasis: a search for therapeutic inhibition.

This review discusses targets of the metastatic cell that may be potentially exploitable with chemotherapy, and presents the current status of several novel, antimetastatic agents.

Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia.

Cysteine proteinases in cancer progression and their clinical relevance for prognosis.

It is proposed that an imbalance between cathepsins and cystatins, associated with the metastatic tumor cell phenotype, may facilitate tumor cell invasion and metastasis and be responsible for early relapse of the disease after removal of the primary tumor.

Bax cleavage is mediated by calpain during drug-induced apoptosis

The results suggest that calpains and caspases are activated during drug-induced apoptosis and thatCalpains, along with caspase, may be involved in modulating cell death by acting selectively on cellular substrates.

Cysteine proteases and tumor progression

It is found that cathepsin B serves as a diagnostic and prognostic marker of tumor progression, whereas in vitro and in vivo studies have shown that cysteine protease inhibitors can reduce tumor cell invasion and metastasis in some systems.

The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis

In a cell-free apoptosis system, mitochondria spontaneously released cytochrome c, which activated DEVD-specific caspases, leading to fodrin cleavage and apoptotic nuclear morphology, and Bcl-2 acts to inhibit cy tochrome c translocation, thereby blocking caspase activation and the apoptotic process.

Double identity for proteins of the Bcl-2 family

The discovery that Bcl-2 can function both as an ion channel and as an adaptor or docking protein is made, indicating that this oncogenic protein can be used as a docking protein or adaptor for ion channels.

The subrenal capsule tumor implant assay as a predictor of clinical response to chemotherapy: 3 years of experience.